News
HCM
12.46
-1.42%
-0.18
CICC Sticks to Its Buy Rating for HUTCHMED (China) (HCM)
TipRanks · 6h ago
Orient Securities Keeps Their Buy Rating on HUTCHMED (China) (HCM)
TipRanks · 10h ago
AstraZeneca Reports Mixed Lung Cancer Trial Outcomes From Three Pivotal Studies
Benzinga · 2d ago
At a glance: stocks gapping up premarket
Seeking Alpha · 2d ago
Weekly Report: what happened at HCM last week (0810-0814)?
Weekly Report · 2d ago
AstraZeneca: Tagrisso Plus Orpathys Phase III Trial Shows PFS, OS Improvements In EGFRm Lung Cancer
NASDAQ · 2d ago
HUTCHMED's ORPATHYS-TAGRISSO Combo Shows Significant PFS, OS Benefit In Phase III Trial
NASDAQ · 2d ago
Reported Sunday, HUTCHMED Says ORPATHYS Plus TAGRISSO Achieved Statistically Significant, Clinically Meaningful PFS And OS Improvements In MET-Driven EGFR-Mutated Lung Cancer
Benzinga · 2d ago
Hutchmed announces results from Saffron Phase III trial of Orpathys, Tagrisso
TipRanks · 2d ago
HUTCHMED (China) (HCM) was downgraded to a Hold Rating at Daiwa
TipRanks · 5d ago
Weekly Report: what happened at HCM last week (0803-0807)?
Weekly Report · 08/10 10:00
HUTCHMED (China) (HCM) Gets a Buy from CICC
TipRanks · 08/07 00:27
HUTCHMED (China) (HCM) Gets a Buy from BOCOM International Holdings Company
TipRanks · 08/04 06:16
UBS Remains a Buy on HUTCHMED (China) (HCM)
TipRanks · 08/04 05:27
UOB Kay Hian Remains a Buy on HUTCHMED (China) (HCM)
TipRanks · 08/04 00:27
Guotai Haitong Keeps Their Buy Rating on HUTCHMED (China) (HCM)
TipRanks · 08/04 00:26
Analysts’ Top Healthcare Picks: Insmed (INSM), HUTCHMED (HCM)
TipRanks · 08/03 12:30
Weekly Report: what happened at HCM last week (0727-0731)?
Weekly Report · 08/03 09:59
Huatai Securities Sticks to Their Buy Rating for HUTCHMED (China) (HCM)
TipRanks · 08/01 05:05
HUTCHMED (China) H1 EPS $0.09 Down From $2.61 YoY, Sales $278.287M Up From $277.677M YoY
Benzinga · 07/30 11:01
More
Webull provides a variety of real-time HCM stock news. You can receive the latest news about Hutchmed (China) Limited through multiple platforms. This information may help you make smarter investment decisions.
About HCM
HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.